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a b s t r a c t
Mammalian lipoxygenases play a role in normal cell development and differentiation but they have also been
implicated in the pathogenesis of cardiovascular, hyperproliferative and neurodegenerative diseases. As lipid
peroxidizing enzymes they are involved in the regulation of cellular redox homeostasis since they produce lipid
hydroperoxides, which serve as an efﬁcient source for free radicals. There are various epidemiological
correlation studies relating naturally occurring variations in the six human lipoxygenase genes (SNPs or rare
mutations) to the frequency for various diseases in these individuals, but for most of the described variations no
functional data are available. Employing a combined bioinformatical and enzymological strategy, which
included structural modeling and experimental site-directed mutagenesis, we systematically explored the
structural and functional consequences of non-synonymous genetic variations in four different human
lipoxygenase genes (ALOX5, ALOX12, ALOX15, and ALOX15B) that have been identiﬁed in the human 1000
genome project. Due to a lack of a functional expression system we resigned to analyze the functionality of
genetic variations in the hALOX12B and hALOXE3 gene. We found that most of the frequent non-synonymous
coding SNPs are located at the enzyme surface and hardly alter the enzyme functionality. In contrast, genetic
variations which affect functional important amino acid residues or lead to truncated enzyme variations
(nonsense mutations) are usually rare with a global allele frequencyo0.1%. This data suggest that there
appears to be an evolutionary pressure on the coding regions of the lipoxygenase genes preventing the
accumulation of loss-of-function variations in the human population.
& 2013 The Authors. Published by Elsevier B.V.
Introduction
Lipoxygenases (LOXs) are lipid-peroxidizing enzymes that cata-
lyze the dioxygenation of poly-unsaturated fatty acids containing a
cis,cis-1,4-pentadiene structure [1]. Together with various oxygen
activating enzymes LOXs increase the cellular oxidizing potential by
biosynthesizing lipid hydroperoxides, which serve as an efﬁcient
source for free radicals unless they are reduced by peroxide reducing
enzymes to the corresponding alcohols [2,3]. LOXs are widely
distributed in terrestrial life since they occur in bacteria, fungi, lower
marine organisms, plants and higher animals [4,5]. In humans six
functional LOX genes (ALOX5, ALOX12, ALOX15, ALOX15B, ALOX12B,
and ALOXE3) have been identiﬁed [1]. The crystal structures of three
different mammalian LOX isoforms (human ALOX5, rabbit ALOX15,
porcine ALOX15) have been solved [6–8] and despite subtle struc-
tural differences there is a high degree of structural similarity
between different LOX isoforms. Human LOXs (hALOX) have been
implicated in the pathogenesis of cardiovascular and inﬂammatory
diseases as well as in various forms of cancer but the detailed
mechanistic basis for their pathophysiological roles is still a matter
of discussion [9–12].
In different epidemiological correlation studies genetic varia-
tions in hALOX genes have been related to an increased risk of
colorectal cancer [13,14], stroke [15], bronchial asthma [16] and
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atherosclerosis [17]. Unfortunately, most of these variations occur
either in intronic, in the promoter or in other non-coding DNA
regions and thus, functional characterization of these genetic varia-
tions is difﬁcult. However, there are scattered reports, in which the
functionality of some genetic variations has been studied: (i) A non-
synonymous SNP in the hALOX12 gene (rs28395860) has been
identiﬁed, which leads to a non-conservative Gln261Arg exchange.
This mutation has been correlated to the pathogenesis of osteoporo-
sis, breast cancer and schizophrenia [18–20]. Unfortunately, func-
tional data on the recombinant enzyme indicated that this mutation
did hardly impact the in vitro enzyme function [21]. (ii) Heterozygous
allele carriers of the hALOX15 Thr560Met SNP (rs34210653) have a
signiﬁcant higher risk for coronary artery disease (CAD) [22]. In vitro
mutagenesis studies indicated that this amino acid exchange leads to
a near null variant of the enzyme and the molecular basis for the loss
in the enzyme activity has been explored in detail [23]. A similar
naturally occurring near null variant (rs61099320) of this enzyme has
recently been described but because of its low occurrence frequency
no epidemiological correlation study has yet been carried out [24].
(iii) Inactive enzyme variations in hALOX12B and hALOXE3 have
been associated with a rare skin dysfunction called autosomal
recessive congenital ichthyosis (ARCI) [25]. (iv) In a recent report
the non-synonymous SNP rs2228065, which leads to a Glu254Lys
exchange in hALOX5, was signiﬁcantly associated with a higher risk
of bronchial asthma [26], whereas it was not associated with an
increased risk of breast cancer [27]. Unfortunately, no functional data
are currently available for this particular enzyme variant.
Completion of the human 1000 Genome project provided an
integrated map of genetic variations in 1092 individuals from all
over the world [28] and the corresponding database (www.1000ge-
nomes.org) also includes a large number of genetic variations in
enzymes and receptors of the arachidonic acid cascade. Although
this database does not sufﬁciently cover the genetic diversity in all
parts of the world, particularly in Southeast Asia [29], it serves as a
suitable source for detailed studies on the functionality of naturally
occurring genetic variants of enzymes, hormones, receptors, and
structural proteins. The aim of this work was to analyze the
functional aspects of non-synonymous coding enzyme variations
in four different hALOX genes to ﬁnd new interesting candidates
which have strong functional effects on position- and stereospeci-
ﬁcity, catalytic activity, thermostability and structure. Of course it is
impossible to analyze all genetic variations and therefore, we
mainly focussed on common SNPs with a published frequency
and variations which are either non-conservative amino acid
exchanges or who affect important amino acid residues. The
N-terminal domain of these enzymes has mainly regulatory func-
tions and even N-terminally truncated enzyme variations showed
catalytic activity in vitro and therefore we focussed on genetic
variations in the catalytic domain of these LOX isoforms. For this
study we took advantage of the 1000 Genome Project database and
evaluated the functionality of different genetic variations in four
hALOX genes employing a combined in silico and in vitro approach,
which involves recombinant protein expression, site-directed muta-
genesis and computer-based structural modeling. Due to a lack of a
functional expression system the genetic variations in hALOX12B
and hALOXE3 are discussed on a theoretical basis.
Material and methods
Materials
The chemicals were obtained from the following sources:
arachidonic acid (5Z,8Z,11Z,14Z-eicosatetraenoic acid), linoleic acid
(9Z,12Z-octadeca-9,12-dienoic acid) and chloramphenicol from
Sigma Aldrich (Hamburg, Germany), HPLC standards of 5(7)-
HETE, 8(7)-HETE, 11(7)-HETE, 12(7)-HETE, 13(7)-HODE,
and 15(7)-HETE from Cayman Chem. (distributed by Biomol,
Hamburg, Germany), sodium borohydride from Aldrich (Steinheim,
Germany), ampicillin from Life Technologies, Inc. (Eggenstein,
Germany), kanamycin and isopropyl-β-thiogalactopyranoside (IPTG)
from Carl Roth GmbH (Karlsruhe, Germany). HPLC solvents were
ordered from Baker (Deventer, Netherlands) or VWR International
GmbH (Darmstadt, Germany). Restriction enzymes were purchased
from Fermentas (St. Leon-Rot, Germany). Oligonucleotide synthesis
was performed at BioTez (Berlin, Germany) and DNA sequencing was
carried out at Euroﬁns MWG Operon (Ebersberg, Germany). The E.
coli strain XL-1 blue was purchased from Stratagene (La Jolla, CA), the
E. coli strain BL21(DE3)pLysS and the ﬂuorescent dye SYPRO Oranges
were purchased from Invitrogen (Carlsbad, California, USA). The
EnBase fed batch system was obtained from the company Biosilta
(Oulu, Finland).
Methods
Recombinant expression and puriﬁcation of hALOX15, hALOX5,
hALOX12 and hALOX15B
In order to express hALOX15 as a His-tag fusion protein, the
coding region of the corresponding cDNA was ﬁrst ampliﬁed by
RT-PCR from human blood and then cloned into the pET28b
expression vector between the SalI (N-terminus) and HindIII
(C-terminus) restriction sites. For the wild-type enzyme and for
each mutant a 0.5 l fed batch liquid culture (EnBase, Biosilta) of E.
coli BL12(DE3)pLysS was grown overnight at 30 1C until an OD600
of about 15 was reached. Expression of the recombinant protein
was then induced by addition of 1 mM IPTG (ﬁnal concentration)
and the culture was kept for 24 h at 23 1C until a ﬁnal OD600 of
25–30. Bacteria were centrifuged (3,600g, 4 1C, 10 min) and resus-
pended in 45 ml phosphate buffered saline (PBS). Cells were lysed
by soniﬁcation, the cell debris was removed by centrifugation
(23,000g, 4 1C, 45 min), and the lysis supernatant was loaded onto
a 2 ml Ni-NTA agarose afﬁnity column. To remove loosely bound
proteins, the column was washed subsequently with 100 mM
Tris/HCl, 300 mM NaCl (pH 8.0) containing either 10 or 25 mM
imidazole. The His-tagged fusion protein was then eluted with
100 mM Tris/HCl, 300 mM NaCl, 200 mM imidazole (pH 8.0).
The elution fractions were desalted and further puriﬁed by anion
exchange chromatography on a ResourceQ column (6 ml) to
electrophoretic homogeneity (purity495%). The puriﬁed enzyme
was stored in 100 mM Tris/HCl, 150 mM sodium chloride in the
presence of 10% (v/v) glycerol (pH 8.0) at 80 1C until use. The
iron content of the ﬁnal LOX preparation was measured by atom
absorbance spectroscopy on a Perkin-Elmer Life Sciences AA800
instrument equipped with an AS800 auto sampler. The iron
content was related to LOX protein that was quantiﬁed spectro-
photometrically (1 mg/ml pure human ALOX results in an absor-
bance of 1.6 at 280 nm).
Expression of hALOX12, hALOX15B and hALOX5 variants was
carried out as previously described [30–31].
Lipoxygenase activity assays
ALOX activity of the puriﬁed LOX preparations was assayed by
RP-HPLC quantiﬁcation of arachidonic acid (AA) oxygenation.
Puriﬁed enzyme (4 mg) was incubated with 100 mM arachidonic
acid for 15 min at 37 1C. The hydroperoxide fatty acids were
reduced to the corresponding alcohols using sodium borohydride
and the sample was acidiﬁed with acetic acid to pH 3. Then 500 ml
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of ice-cold methanol was added, protein precipitate was centri-
fuged (14,000g, 8 1C, 10 min) and aliquots of the clear supernatant
were injected to RP-HPLC.
Kinetic measurements were performed using an UV-2102
UV/VIS Scanning Spectrophotometer (Shimadzu, Japan) measuring
the increase of absorbance at 235 nm. When linoleic acid was used
as a substrate 1.6 mg of puriﬁed enzyme was incubated with
different concentrations of this fatty acid (1–100 mM) in 1 ml PBS
and the formation of conjugated dienes was followed at 235 nm
over 60 s.
Activity assays for hALOX12, hALOX15B and hALOX5 variants
were carried out as previously described [30–31].
LTA4 Synthase activity of hALOX5 was measured using a
modiﬁed ALOX5 activity assay [31], while 25 mM 5 S–H(p)ETE
was used as substrate. The reaction was stopped after 30 min by
adding ice-cold methanol to the reaction mix in the ratio of 1.5:1.
The total mix was then analyzed by RP-HPLC measuring the
formation of conjugated trienes at 270 nm.
HPLC analysis
HPLC of the LOX products was performed on a Shimadzu LC-20
instrument equipped with an auto sampler recording the absor-
bance of the efﬂuent at 235 nm. Reverse phase-HPLC was carried
out on a Nucleodur C18 Gravity column (Macherey-Nagel, Düren,
Germany; 2504 mm, 5 mm particle size) coupled with a guard
column (84 mm, 5-mm particle size). A solvent system of
methanol/water/acetic acid (85/15/0.05, by vol) was used at a ﬂow
rate of 1 ml/min. Straight phase-HPLC (SP-HPLC) was performed
on a Nucleosil 100-5 column (2504 mm, 5 mm particle size) with
the solvent system n-hexane/2-propanol/acetic acid (100/2/0.1, by
vol) and a ﬂow rate of 1 ml/min. Enantiomers of hydroxylated fatty
acids were separated by chiral phase HPLC (CP-HPLC) employing
different types of Chiralcel (Daicel Chem. Ind., Ltd.) columns.
As mobile phase a mixture of n-hexane/2-propanol/acetic acid at
a ﬂow rate of 1 ml/min was used, in which the 2-propanol content
was varied for the different positional isomers: 15-HETE: Chiralcel
OD column, 5% 2-propanol; 5-HETE: Chiralcel OB column, 4%
2-propanol. 8- and 12-HETE were additionally separated by a
solid-phase HPLC and then methylated using diazomethane.
Enantiomers of 8-HETE-methylester were separated on a Chiralcel
OB column with a solvent system n-hexane/2-propanol/acetic
acid (100/4/0.1, by vol) and 12-HETE-methylester enantiomers
were separated on a Chiralcel OD column with a solvent system
(100/2/0.1, by vol).
Thermal shift assay (thermal denaturation)
Puriﬁed LOX enzyme (3 mM) was incubated with a 2.5-fold
molar excess of ﬂuorescent dye SyproOranges in 20 mM Tris/HCl
containing 150 mM NaCl (pH 8.0), total volume 20 ml. The heat
denaturation reaction was performed on a Rotor-Gene RG-3000
real-time PCR machine (Corbett Research, Qiagen, Hilden,
Germany) heating up the probes from 30 to 95 1C at a rate of
0.5 1C/s. The ﬂuorescent dye SyproOranges is quenched in aqu-
eous solutions and becomes detectable after binding to hydro-
phobic molecules. Thermal unfolding of the protein induces
surface exposure of hydrophobic core regions, where the dye is
able to bind. Fluorescence intensity was quantiﬁed using a FAM/
SYBR green ﬁlter. The software Rotor-Gene 4.6 was used for
calculation of the negative ﬁrst derivative of the raw data. Figures
were generated with SigmaPlot. The melting temperature (Tm) for
each mutant was analyzed in 3–4 independent experiments.
Immunoblotting
To quantify the relative amounts of different hALOX12 and
hALOX5 variations in different enzyme preparations, immunoblot-
ting was carried out as previously described using an anti-his-tag
antibody [30–31].
Structural modeling, analysis and amino acid alignment
The crystal structure of the rabbit ALOX15 (PDB: 2P0M) was
used as template to model the 3D-structure of the human enzyme.
The rabbit ALOX15 shares a high degree of amino acid identity
(480%) with the human ortholog and thus such modeling is
plausible. The structure of the stable ALOX5 (PDB: 3O8Y) was used
as for structural analysis of hALOX5 variations. A protein model
from the Protein model database (PMDB) was used for structural
analysis of human ALOX15B (PMDB code: PM0078035) [32]. The
models for hALOX12 and hALOXE3 were generated with the
homology modeling web server M4T (Albert Einstein College of
Medicine, New York USA) [33–34]. The resulting structures were
reﬁned using the protein structure reﬁnement server 3Dreﬁne
[35]. All structures were then solvated in TIP3 explicit water
models and subjected to energy minimization in the program
NAMD [36]. CHARMM27 [37] force ﬁeld parameters were used and
structures were minimized by 250,000 steps. Model quality
estimation was performed with the Qmean quality estimation
server [38]. The visualization software program PyMol (Schrodin-
ger, New York, USA) was used for structural analysis and ﬁgure
preparation. Multiple sequence alignment was performed with
the ClustalW2 program (European Bioinformatics Institute,
Cambridge, UK) setting default parameters. ALOX sequences were
extracted from the NCBI database (Bethesda, USA) and the infor-
mation about the natural occurring hALOX variations was taken
from the 1000 Genome database (www.1000genomes.org).
Results
ALOX15 (human 15-lipoxygenase)
Human ALOX15 consists of 662 amino acids and its sequence
was ﬁrst published in 1988 [39]. In the 1000 Genome database 94
non-synonymous coding variations are described (Table 1). Two of
them, Pro617Ser and Thr560Met, have a global allele frequency
of41% and are therefore classiﬁed as SNPs (Table S1). Since it is
impossible to test the functional consequences of all existing
genetic variants we selected ﬁve non-conservative amino acid
exchanges (Arg205Gln, Gly422Glu, Gly422Arg, Thr560Met, and
Pro617Ser) in the catalytic domain of the enzyme for more
detailed investigations. These mutants together with the wildtype
enzyme were recombinantly expressed, puriﬁed to apparent
Table 1
Non-synonymous coding variations in six human lipoxygenase genes published in
the 1000 Genome database (www.1000genomes.org).
ALOX
isoform
sum Number of non-synonymous coding variations
SNPs
(Frequency41%)
Rare missense mutations
(Frequencyo1%)
Nonsense
mutations
ALOX15 94 2 84 8
ALOX5 69 1 68 0
ALOX12 67 2 64 1
ALOX15B 86 6 76 4
ALOX12B 69 1 68 0
ALOXe3 83 2 75 6
total 468 14 435 19
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homogeneity and characterized with respect to their enzymatic
properties.
When we analyzed the structural position of the selected
variations in the 3D-structure of the ALOX15 enzyme we found
that two variations (Arg205Gln, Pro617Ser) (Fig. 1A) are localized
on the enzyme surface with no immediate connection to the active
site. In contrast, the Thr560Met and Gly422Glu/Arg are buried
deeply inside the protein in close proximity to the active site
(Fig. 1A). This localization might explain why these variants
(Thr560Met, Gly422Glu) were catalytically silent (Table 2) which
is consistent with previous reports [23–24]. The surface exposed
mutants (Arg205Gln, Pro617Ser) exhibited a similar speciﬁc diox-
ygenase activity as the wildtype enzyme. Moreover, the reaction
speciﬁcity was hardly altered since 15-H(p)ETE was the major
(74–96%) arachidonic acid oxygenation product for both enzyme
variants (Fig. 1B). To explore the structural consequences of the
amino acid exchanges we monitored the thermostability of wild-
type and mutant enzymes. We found that the enzymatic active
Fig. 1. Genetic variations in human ALOX15 (A) Structural localization of analyzed hALOX15 variations (PDB: 20PM). The N-terminal β-barrel domain is shown as yellow
cartoon; the catalytic domain is represented as marine blue cartoon. The amino acid variations are shown as red spheres. (B) Reverse-phase HPLC of hALOX15 wildtype and
different genetic variations. The chromatograms show that the wildtype and the Pro617Ser, Gly422Arg, Arg205Gln variations have a major 15- and minor 12- arachidonate
oxygenation speciﬁcity while the Gly422Glu variation is inactive. The small peaks in the HPLC proﬁle originate from arachidonic acid autoxidation. (C) Thermostability of
hALOX15 wildtype and different genetic variations using a ﬂuorescent-based thermodynamic shift assay. The thermal denaturation curve of the Pro617Ser, Arg205Gln,
Gly422Arg variations are similar to the wildtype enzyme, whereas the Gly422Glu variation is different. The negative ﬁrst derivative is calculated to determine the inﬂection
point (Tm) of the unfolding curve more accurately. (D) Michaelis–Menten kinetics of different hALOX15 variations. The wildtype enzyme and the Pro617Ser, Arg205Gln,
Gly422Arg variations follow Michaelis–Menten kinetics whereas the Thr560Met and Gly422Glu variations are catalytically silent.
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variants showed a similar denaturation behavior as the wildtype
enzyme, while the melting curves for the inactive enzyme varia-
tions (Gly422Glu, Thr560Met) were quite different (Fig. 1C). For
these enzyme species the ﬂuorescence levels were already high at
lower temperatures (30 1C) and did not signiﬁcantly increase
when the temperature was elevated. In fact, for these enzyme
species a true melting temperature (Tm) could not be determined
(Fig. 1C). Mechanistically, this data suggest a high degree of
misfolding in the corresponding enzyme variants, which is a
plausible reason for their inactivity.
The kinetic properties of the catalytically active enzyme species
(Arg205Gln; Pro617Ser; Gly422Arg) were not dramatically impaired
by the genetic variations, since they had similar kinetic parameters
(Fig. 1D) as the wildtype enzyme with low Km values for linoleic acid
(1.2–4.8 mM) and molecular turnover rates (kcat) between 9.6 and
22.4 s-1 (Table 3).
For all LOX enzymes described so far the C-terminal amino acid
functions as iron ligand and previous mutagenesis studies showed
that deletion of this residue leads to a loss of catalytic activity [4].
In the 1000 Genome database eight nonsense mutations have
been identiﬁed (Table 1). These genetic variations are likely to
encode for truncated and inactive enzyme species and homozy-
gous allele carriers should be completely hALOX15 deﬁcient.
Unfortunately, for neither of these nonsense mutations a global
allele frequency has been reported suggesting that this mutation
was only found once in the 1000 Genome database. In other
words, the allele frequency should beo0.1% (Table S1.).
Next we speciﬁcally searched in the 1000 Genome database for
genetic variations of other functionally important amino acid
residues (iron ligands, speciﬁcity determinants). All LOXs identi-
ﬁed so far carry a redox active metal (iron or manganese) in the
active site [1,4] and for hALOX15 His360, His365, His540, His544,
and the C-terminal Ile662 constitute the direct iron ligands [6].
Neither of these residues was affected by a genetic variation.
hALOX15 exhibits a dual positional speciﬁcity [4] and the side
chains of Phe352, Ile417, Ile592 play a major role for this enzyme
property [40]. Analyzing the data obtained in the 1000 Genome
database we found a rare variation at Phe352, in which the
bulky Phe is exchanged to a less space-ﬁlling Leu (rs143365387).
According to the triad concept, this enzyme variant should be a
12-lipoxygenating enzyme species and previous mutagenesis
studies conﬁrmed this conclusion [40]. This data indicate that
homozygous allele carriers express a 12-lipoxygenating enzyme
species and it would be of major interest whether such humans
have any functional defects. Unfortunately, because of the low allele
frequency the search for such homozygous allele carriers is rather
laborious and the existence of such individuals is even questionable.
Previous amino acid alignments indicated that most S-LOXs
carry an Ala at a critical position (Coffa/Brash determinant)
whereas R-LOXs have a small Gly at this position. Although this
concept is not applicable for all lipoxygenases [41] mutagenesis
studies on different isoforms showed that Ala-to-Gly exchanges at
this position increase the share of R-HETE isomers [41–42]. In
hALOX15 Ala403 is the corresponding residue but so far there is no
human genetic variation described for this position.
Membrane binding upregulates the catalytic activity of ALOX15
[43] but it is also a prerequisite for LOX catalyzed oxygenation
of membrane lipids [43]. Surface exposed hydrophobic amino
acids such as Tyr15, Leu70, Leu71, Lys180 and Leu194 have
been implicated in membrane binding [44] and the human 1000
genome project has published genetic variations for two of these
residues (Table S1.). Tyr15His (rs13306168) has a global frequency
of 0.6% whereas no frequency data are available for the Leu194Pro
exchange (rs11867874). Both mutations constitute more or less
conserved amino acid exchanges and thus, only minor effects on
membrane binding might be predicted.
In silico docking studies and molecular dynamic simulations
with different fatty acid substrates suggested that Arg402 and
Phe414 may be involved in substrate binding [45–46]. For Arg402
two rare genetic variations with a global frequencyo1% have been
identiﬁed in the 1000 Genome database [Arg402Gln (TMP_ESP_
17_4536752) and Arg402Trp (rs144038526)]. To obtain informa-
tion of the functional relevance of these amino acid exchanges we
expressed the Arg402Trp mutant of hALOX15 and performed activity
and thermostability assays. Arg402Trp has a reduced catalytic activity
(36% residual activity) while its thermostability and positional
speciﬁcity was hardly affected. Nevertheless the reduced catalytic
activity is not as dramatic as it is for two previous mentioned loss-
of-function mutations, so one can assume that this variation has only
minor functional effects (Table 2).
ALOX5 (human 5-lipoxygenase)
hALOX5 consists of 674 amino acids and its sequence was ﬁrst
published in 1988 [47]. It is the key enzyme in the biosynthesis of
leukotrienes [1,48] and converts arachidonic acid (AA) mainly to
5S‐H(p)ETE. In addition, it catalyzes the dehydration of 5S‐H(p)ETE
to the allylic epoxide leukotriene A4 (LTA4) which can then be
further metabolized by other enzymes (LTA4H, LTC4S, γ-glutamyl
transferases, dipeptidases) to leukotrienes [1,48]. Leukotrienes
(LTs) are pro-inﬂammatory mediators, which play a role in the
pathogenesis of bronchial asthma and allergic rhinitis [1]. In the
1000 Genome database there are 69 non-synonymous coding
variations described for hALOX5 (Table 1) but only the hALOX5
Glu254Lys (rs2228065) variant has a global frequency41% and is
therefore deﬁned as SNP. We selected seven non-synonymous
coding variations in the catalytic domain of this enzyme for more
Table 2
Relative catalytic activities and melting points of different hALOX15 variations.
hALOX15 variation ID Global allele
frequency (%)
15-
HETE
(%)
Rel.
activity
(%)
Melting
point Tm
(1C)
wildtype 9374 10076 50.070.6
Arg205Gln rs11568101 0.5 8976 8977 50.470.1
Arg402Trp rs144038526 0.1 7772 3673 50.570.2
Gly422Glu rs61099320 o 0.1 8374 o 1 n.d.
Gly422Arg rs147238486 0.1 8772 4674 47.670.1
Thr560Met rs34210653 1.5 7475 o 2 n.d.
Pro617Ser rs41432647 1.0 9671 141717 51.070.2
Puriﬁed recombinant hALOX15 wildtype and the different variations were incu-
bated with arachidonic acid as described in Material and Methods (n¼4). The
amounts for 15-HETE were quantiﬁed for each sample, and wild-type 15-HETE
formation was set to 100%. Thermal shift assays were performed as described in
Material and Methods. The inﬂection point of the ﬁrst negative derivative
represents the melting point (Tm) of the enzyme variation.
Table 3
Kinetic parameters of different hALOX15 variations.
hALOX15 variation ID kcat (s-1) Km R2
wildtype – 14.470.8 3.871.0 0.89
Arg205Gln rs11568101 12.771.2 1.270.8 0.84
Gly422Glu rs61099320 – – –
Gly422Arg rs147238486 9.670.7 1.770.8 0.96
Thr560Met rs34210653 – – –
Pro617Ser rs140549513 22.471.5 4.87 1.3 0.95
Puriﬁed recombinant hALOX15 wildtype and the different variations were incu-
bated with linoleic acid as described in Material and Methods (n¼3). The formation
of conjugated dienes was followed by recording the increase in absorbance at
235 nm for 60–120 s on the spectrophotometer. The resulting turnover rates (kcat)
and Michaelis constants (Km) are given. The R square value (R2) represents the
accuracy of the hyperbolic equation.
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detailed functional analysis (Table 4). Structural localization of the
altered amino acids revealed that except the Ala549Val variation,
which is buried deeply inside the enzyme, all other variations are
localized at the enzyme surface suggesting that they might have
only minor effects on enzyme functionality (Fig. 2A). Site directed
mutagenesis conﬁrmed this hypothesis since the enzyme mutants
exhibited similar reaction speciﬁcities and speciﬁc dioxygenase
activities (Fig. 2B.). All mutants converted arachidonic acid to 5-H
(p)ETE as the major reaction product (Fig. 2B) and their relative
catalytic activities varied between 22% and130% when compared
to the wildtype enzyme (Table 4). The Ala549Val variation
(rs113388968) shows the strongest reduction of dioxygenase
activity (loss of 78%) and this impairment might be related to its
close proximity to the iron ligand sphere [7]. We also analyzed the
effect of two genetic variations on the LTA4 Synthase activity of
hALOX5 and found that it was hardly affected by the two analyzed
variations (Glu254Lys, Thr591Met) and this is consistent with our
data for dioxygenase activity (Table S2.).
In contrast to ALOX15, no nonsense variation that leads to the
expression of a C-terminally truncated enzyme has been described
for hALOX5 in the database (Table 1).
As for ALOX15 we speciﬁcally searched the 1000 Genome
database for genetic variations of other functionally important
amino acid residues (iron ligands, speciﬁcity determinants,
FY-cork, activator binding sites). His368, His373, His551, Asn555
and the C-terminal Ile674 coordinate the non-heme iron [7,48] but
no variation has been described for any of these residues. Similarly,
we did not ﬁnd any mutants (Table S1) for the triad residues [49]
and for the enantioselectivity determinant [41–42]. The substrate
binding pocket of hALOX5 is an elongated cavity, which appears to
be sealed at both ends for the ligand free protein. Phe178 and
Tyr182 (FY-cork) close the cavity at one end [7] and Trp148 may
block the opposite entrance to the cavity. Neither for the FY-cork,
nor for Trp148 has any genetic variations been described.
There are numerous hALOX5-activating factors (Ca2þ , phos-
phatidylcholine, ATP, coactosin-like protein) and for some of them
the binding mechanisms have been identiﬁed. For instance, Asn44,
Asp45, and Glu47 are required for Ca2þ-binding [1,48]. For binding
of the enzyme to biomembranes and phosphatidyl choline (PC)
vesicles Trp13, Trp75, and Trp102 appear to be important [1,48].
However, for none of these residues genetic variations have been
described.
In vitro kinase assays suggested that phosphorylation of speciﬁc
amino acid residues (Ser271, Ser523, and Ser663) regulates the
enzyme functionality [1,48]. There is a rare genetic variation at
Ser271 in the database (Ser271Ile, TMP_ESP_10_45920561), which
should prevent enzyme phosphorylation at this position.
ALOX12 (human platelet 12-lipoxygenase)
hALOX12 contains 663 amino acids and was the ﬁrst mamma-
lian lipoxygenase described back in 1974 [50]. In the 1000 Genome
database there are 67 non-synonymous coding variations for this
enzyme (Table 1). Two of them, Gln261Arg (rs28395860) and
Asn322Ser (rs434473) have a high global allele frequencyo 1%
(38.8% and 34.4% respectively) (Table S1.). In total we analyzed
four selected non-synonymous coding variations in the catalytic
domain of the hALOX12 gene (Asp134His, Glu259Lys, Gln261Arg,
and Asn322Ser). Structural analysis indicated that all of these
amino acid exchanges are located on the enzyme surface and
therefore only minor functional effects can be expected (Fig. 3A).
In fact, the speciﬁc activity of all mutants was comparable
(60-109%) to that of the wildtype enzyme (Fig. 3B) and 12-H(p)
ETE was always the dominant reaction product for all enzyme
variations (Table 5). Interestingly, the Gln261Arg exchange was
also found in two Homo Neanderthalensis individuals [51].
One premature stop variation (Arg348stop, rs141346813) lead-
ing to a C-terminally truncated enzyme was found in the 1000
Genome database but since no frequency data are given it must be
classiﬁed as rare enzyme mutation.
Similar to hALOX15 and hALOX5 we speciﬁcally searched the
1000 Genome database for genetic variations of other functionally
important amino acid residues (iron ligands, position- and enantio-
selectivity determinants). The catalytic iron ion is coordinated by the
residues His360, His365, His540, Asn544, and Ile663. The triad
concept is partly applicable for this enzyme [52] and the hALOX12
carries an Ala at the critical enantioselectivity position 403 indicat-
ing that it is an S-LOX [41–42]. Neither for the iron coordination nor
for the position- (Phe353, Ala417, and Ile593) and enantioselectivity
determinants (Ala403) has any genetic variation been described
(Table S1.). As for hALOX15 Arg402 of hALOX12 may play a role
for positioning of the fatty acid substrate within the active site
[45–46]. Arg402Gln (rs143539715) is a rare enzyme variant of this
LOX isoform but the functional consequences of this amino acid
exchange have not been explored.
ALOX15B (human 15-lipoxygenase type II)
This enzyme consists of 676 amino acids (Isoform D) and was
ﬁrst discovered in 1997 [53]. 86 non-synonymous coding varia-
tions have been identiﬁed in the 1000 Genome database and six of
them have a global allele frequency41% (Table 1): Pro77Ala
(rs78230493), Ala311Val (rs148602477), Arg486His (rs9895916),
Arg635Gln (rs61730298), Gln656Arg (rs4792147), and Ile676Val
(rs7225107) (Table S.1). We selected three frequent genetic varia-
tions (Arg486His, Gln656Arg and Ile676Val) in the catalytic
domain of the enzyme for more detailed characterization. Two
of them (Arg486His, Gl656Arg) are located at the enzyme surface
and therefore only minor functional effects were expected. In con-
trast, Ile676 is an iron ligand and Ile676Val exchange might impact
the functionality of the enzyme (Fig. 4A). Functional analysis showed
that none of the analyzed hALOX15B SNPs dramatically altered
the position speciﬁcity (Fig. 4B) and speciﬁc activity (Table 6) of the
enzyme.
Thermal denaturation studies (Fig. 4C) indicated a two-state
unfolding curve for all analyzed hALOX15B variations and analysis
of the ﬁrst derivative of the denaturation curves showed that the
Ile676Val mutant has a slightly reduced melting temperature (Tm).
This data suggest that the Ile676Val exchange destabilizes the
enzyme structure to a certain degree. In contrast, the wildtype
enzyme, the Arg486His and Gln656Arg mutants have similar
melting curves and thus, these mutations did not impact the
enzyme structure (Table 6). The basic kinetic constants Km and kcat
(Fig. 4D) were similar for the wildtype enzyme and the different
Table 4
Relative catalytic activities and product speciﬁcities of different hALOX5 variations.
hALOX5 variation ID Global allele frequency
(%)
5-HETE
(%)
Rel. activity
(%)
wildtype 7471 10072
Glu254Lys rs2228065 7.5 9071 5875
Pro337Ser rs28395860 0.1 8571 5471
Ala447Ser rs28395869 0.0 8171 11875
Ala549Val rs113388968 o 0.1 8471 2271
Pro577Leu rs143439556 o 0.1 8971 9574
Thr591Met rs146768497 o 0.1 8671 13077
Lys656Gln rs147238486 0.0 8072 12273
hALOX5 aliquots of the Co-Sepharose elution fraction 2 containing equal amounts
of LOX protein as determined by western blot analysis were used for activity assays
(n¼4). The amounts of HETE isomers were analyzed for each sample by HPLC and
are used to calculate the catalytic activity of the different enzyme species. The HETE
formation of the wildtype was set to 100%.
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Fig. 2. Genetic variations in human ALOX5 (A) Structural localization of analyzed hALOX5 variations (PDB: 3O8Y). The N-terminal β-barrel domain is shown as yellow
cartoon; the catalytic domain is represented as marine blue cartoon. The amino acid variations are shown as red spheres. (B) Reverse-phase HPLC chromatogram of hALOX5
wildtype and different genetic variations. The chromatograms show that the wildtype and the hALOX5 variations are major 5-lipoxygenating enzymes. The Ala549Val
variation shows the strongest reduction in catalytic activity but also forms 5-H(p)ETE as major oxygenation product.
T. Horn et al. / Redox Biology 1 (2013) 566–577572
Fig. 3. Genetic variations in human ALOX12 (A) Structural localization of analyzed hALOX12 variations (hALOX12 model) N-terminal β-barrel domain is shown as yellow
cartoon, the catalytic domain is represented as marine blue cartoon. The analyzed amino acid variations are shown as red spheres. (B) Reverse-phase HPLC chromatogram of
hALOX12 wildtype and different genetic variations. The RP-HPLC chromatograms show that the wildtype and the hALOX12 variations are 12-lipoxygenating enzymes.
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mutants (Table 7) indicating that the mutations had only minor
effects on substrate binding and oxygenation rate. There are four
premature stop variations described (Table 1) in the 1000 Genome
database but neither of them has a global allele frequency of41%.
In hALOX15B the catalytic iron is coordinated by His373,
His378, His553, Ser557, and the C-terminal Ile676. Interestingly,
Ile676Val is a SNP with a global allele frequency of 9.6%, but our
activity data indicated the lack of functional consequences for the
amino acid exchange (Fig. 4C.). hALOX15B exhibits a single posi-
tion speciﬁcity, as it converts arachidonic acid almost exclusively
to 15-H(p)ETE [53]. The ortholog enzyme of mice (Alox15b) is an
8-lipoxygenating enzyme, and two amino acids Tyr603 and His604
are responsible for this functional difference [54]. In hALOX15B
Asp603 and Val604 are at this position and previous mutagenesis
Table 5
Relative catalytic activities and product speciﬁcities of different hALOX12 variations.
hALOX12 variation ID global frequency
(%)
12-HETE
(%)
rel. activity
(%)
wildtype 4 99 100723
Asp134His rs114985038 0.4 4 99 109736
Glu259Lys rs4987104 0.0 4 99 60718
Gln261Arg rs1126667 38.8 4 99 91710
Asn322Ser rs434473 34.4 4 99 101723
Recombinant expression of hALOX12 and product HPLC analysis was performed as
described in Materials and Methods with crude bacterial lysate supernatant of 5 ml
bacterial cultures (n¼5–10 for each variation). LOX content was determined by
western blot analysis and HETE formation was correlated to the amount of
recombinant protein. The amounts of HETE isomers were analyzed for each sample
by HPLC and are used to calculate the catalytic activity of different enzyme species.
The HETE formation of the wildtype was set to 100%.
Fig. 4. Genetic variations in human ALOX15B (A) Structural localization of analyzed hALOX15B variations (PMDB: PM0078035) N-terminal β-barrel domain is shown as
yellow cartoon; the catalytic domain is represented as marine blue cartoon. The amino acid variations are shown as red spheres. (B) Reverse-phase HPLC chromatogram of
hALOX15B wildtype and different genetic variations. The RP-HPLC chromatograms show that the wildtype enzyme and the Arg486His, Gln656Arg, Ile676Val variants are
15-lipoxygenating enzymes, whereas the Ala416Asp mutant is catalytically silent. The small peaks in the HPLC proﬁle originate from arachidonic acid autoxidation.
(C) Thermostability of hALOX15B wildtype and different genetic variations using a ﬂuorescent-based thermodynamic shift assay. The thermal denaturation curve of the
Arg486His, Gln656Arg, and Ile676Val are similar to the wildtype enzyme, but the proﬁle for the Ala416Asp variant is different indicating structural differences. The negative
ﬁrst derivative is calculated to determine the inﬂection point (Tm) of the unfolding curve more accurately. (D) Michaelis-Menten kinetics of hALOX15B wildtype and different
genetic variations. All analyzed enzyme species follow Michaelis-Menten kinetics.
Table 6
Relative catalytic activities and melting points of different hALOX15B variations.
hALOX15B Variation ID Global
frequency
(%)
15-HETE
(%)
Rel.
activity
(%)
Melting
temperature
Tm (1C)
wildtype 4 99 10072 57.470.2
Arg486His rs9895916 8.7 4 99 10072 56.670.3
Gln656Arg rs28395869 38.6 4 99 10471 56.970.2
Ile676Val rs7225107 10.3 4 99 9477 55.070.3
Ala416Asp rs140152561 0.1 n.d. n.d. n.d.
Puriﬁed recombinant hALOX15B wildtype and the different enzyme variations
were incubated with arachidonic acid as described in Material and Methods (n¼4).
The amounts for 15-HETE were quantiﬁed for each sample, and wildtype 15-HETE
formation was set to 100%. Thermal shift assays were performed as described in
Material and Methods. The inﬂection point of the ﬁrst negative derivative
represents the melting temperature (Tm) of the enzyme variation.
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studies (Tyr603AspþHis604Val) converted the mice 8-LOX to a
15-lipoxygenating enzyme. In the 1000 Genome database there is
a rare natural occurring variant Val603Ile (rs192653434) with
a global frequency of 0.1% at this position (Table 1) but the
functional consequences of this amino acid exchange have not
been studied. One might assume that an Ile-to-Val exchange
represents a conservative mutation and therefore only minor
functional effects should be expected. hALOX15B carries an Ala
at the critical enantioselectivity determinant and therefore it has
been classiﬁed as S-LOX [41–42]. Interestingly, there exists a rare
genetic variation at amino acid position 416 (rs140152561), which
leads to an Ala-to-Asp exchange. In vitro, this mutation causes
inactivity of the enzyme (Fig. 4B) and thermal denaturation curve
of this mutant strongly differs from those of the functional active
SNPs and the wildtype enzyme (Fig. 4C) suggesting that the
3D-structure of the Ala416Asp mutant is severely hampered. To
the best of our knowledge this is the ﬁrst hALOX15B loss-of-
function variation that has been published so far. Nevertheless its
allele frequency is very low and therefore homozygous carriers of
this mutation cannot be expected (Table S1.).
ALOX12B (human 12-lipoxygenase, 12R type)
This LOX isoform consists of 701 amino acids and was ﬁrst
described in mouse and human skin [55–57]. Sixty nine non-
synonymous coding variations have been published in the 1000
Genome database. There are no variations in the database leading
to premature stop codons. Since recombinant expression of this
particular LOX isoform in bacteria was not successful we were
not able to test the functional consequences of the amino acid
exchanges. Thus, we judged the probability of functional alterations
on the basis of the character of the mutations. Multiple amino acid
sequence alignments of many LOXs (see supporting information)
suggested that the catalytic iron in hALOX12B is coordinated by
His398, His403, His578, Asn582, and the C-terminal Ile701 (Table 1).
There is a genetic variation (rs140063508) leading to a His398Tyr
exchange but since Tyr in principle may also function as iron ligand
via its phenolic OH-group we do not expect functional conse-
quences for this amino acid exchange. A multiple sequence align-
ment with sequences of 153 LOX enzymes in different species
indicated that the ﬁrst three iron coordination ligands seem to be
invariable (His) throughout the LOX enzyme family (data not
shown), while the fourth (His, Asn, Ser, or Gly) and the C-terminal
ligand (Ile, Val) are variable. The previous ﬁnding that Ser, which
also contains a hydroxyl group, can function as an iron coordination
ligand supports the idea that a His-to-Tyr exchange might only have
minor functional effects. Searching the 1000 Genome database we
did not ﬁnd genetic variations for the triad residues or for the
enantioselectivity determinants.
hALOX12B knockout mice show a strong phenotype since
homozygous newborn die because of dehydration several hours
after delivery [58]. In humans, genetic variants in the hALOX12B
gene have been related to the development of autosomal recessive
congenital ichthyosis (ARCI) [25]. Some of these mutants have
been picked up in human 1000 genome project (Table S1), but
except for Pro127Ser (rs72842957), which has a global frequency
of 1.1%, the others must be classiﬁed as rare enzyme mutations.
These data are consistent with the fact that ARCI is a rare skin
disease (1:200,000-300,000 Europeans and Northern Americans).
Unfortunately, the Pro127Ser variant is not expressed in HEK 293
cells and thus, no functional data are currently available [25]. If
this variation with its relatively high global allele frequency
of41% would be a strong inducer of ARCI a much higher
prevalence of this skin disease should be expected [25].
ALOXE3 (epidermis-type lipoxygenase 3)
This LOX isoformwas also discovered in mouse and human skin
[59–60]. It has a length of 711 amino acids and a molecular weight
of 80.6 kDa. Eighty three non-synonymous coding variations have
been published in the human 1000 genome database (Table 1), but
only two of them (Ile515Val, rs3027205; Arg678Cys, rs143246503)
have a global frequency41% (3.0% and 1.9%, respectively). Ile515-
Val is a conserved amino acid exchange while Arg678Cys is not
conserved but localized on the enzyme surface far from the active
site and therefore for both SNPs only minor functional conse-
quences can be predicted (see supplement S3.).
As shown for hALOX12B variations in the hALOXE3 gene have
been associated with ARCI [25] and some of themwere also found in
the 1000 Genome database (Table 1). For instance, the Ile515Val
exchange was found in ichthyosis patients, but it remains unclear
whether this mutation really impacts the functionality of the
enzyme [25]. If this genetic variation would be the major cause of
ARCI a much higher prevalence of this disease should be expected.
Searching in the 1000 Genome database we did not ﬁnd any
genetic variation leading to the introduction of a premature
stop codon.
In comparison to other lipoxygenases which have a dioxygen-
ase activity, hALOXE3 is mainly a hydroperoxide isomerase con-
verting hydroperoxides (HpETEs) to speciﬁc epoxyalcohols [61],
although it can also act as a dioxygenase after hydroperoxide
activation [62].
hALOXE3 carries an Ala at the critical enantioselectivity position,
and therefore it can be classiﬁed as S-LOX. This particular enzyme
seems to follow the Coffa/Brash principle since the Ala-to-Gly
exchange increases the R-product formation [63]. However, the
enzyme does not follow the triad concept. Neither the potential iron
ligands nor the enantioselectivity determinant is affected by any
genetic variation.
Discussion
LOXs are lipid peroxidizing enzymes and their intracellular
activity contributes to the regulation of the cellular redox home-
ostasis [2–3]. Since the cellular redox state is an important
regulator of the gene expression pattern, SNP-induced dysfunc-
tionality of LOX isoforms is likely to alter the cellular phenotype.
To quantify the probability of genetically caused LOX dysfunction
we screened the 1000 Genome database for all six human
LOX genes and detected more than 450 non-synonymous coding
variations (www.1000genomes.org). However, only 14 of them can
be classiﬁed as SNPs (global allele frequency41%) while variations
with a lower frequency must be classiﬁed as rare enzyme muta-
tions. Functional analysis of eight SNPs throughout the hALOX
family showed that except from the previously characterized
hALOX15 near-null SNP Thr560Met (rs34210653) all other hALOX
Table 7
Kinetic parameters of different hALOX15B variations.
hALOX15B variation ID kcat (s-1) Km R2
wildtype – 0.1870.01 1.271.2 0.82
Arg486His rs9895916 0.2770.02 2.870.8 0.98
Gln656Arg rs28395869 0.2570.02 3.770.2 0.98
Ile676Val rs7225107 0.1270.01 1.070.6 0.93
Puriﬁed recombinant hALOX15B wildtype and different variations were incubated
with linoleic acid as described in Material and Methods (n¼3). The formation of
conjugated dienes was followed by recording the increase in absorbance at 235 nm
for 120 s. The resulting turnover rates (kcat) and Michaelis constants (Km) are given.
The R square value (R2) represents the accuracy of the hyperbolic equation.
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SNPs had similar enzymatic properties (positional speciﬁcity,
catalytic activity, thermostability) as the corresponding wildtype
enzymes. Structural analysis showed that most of the analyzed
SNPs are located at the enzyme surface, and therefore only minor
effects on enzyme functionality have been predicted (Figs.1–4).
Most of the LOXs carry a catalytic iron at the active site and the
C-terminal Ile is required for metal ion coordination in the active
site [1,4]. Thus, all genetic variations leading to the introduction of
premature stop codons are loss-of-function mutations. So far, 19
nonsense variations have been detected in all six hALOX genes, but
neither of them has a global allele frequency40.1% indicating that
all are rare enzyme mutations.
We found that almost all published hALOX loss-of-function
variations have a global allele frequency ofo0.1%. In contrast, all
more common variations (SNPs) were without major functional
consequences. This ﬁnding is consistent with a conclusion drawn
previously, that rare SNPs and mutations (global allele frequen-
cyo5%) have a higher tendency to be related to a certain disease
and it was suggested that future studies should focus more on
them [28,64]. A major problem with such rare genetic variations is
that they are often only discovered once or twice in large human
populations and their observation is often restricted to one ethnic
subpopulation [28]. Some of such subpopulations have not been
adequately considered when the human 1000 Genome project was
structured [29]. Thus, larger genome studies with up to 10,000 and
more people and a broader spectrum of different ethnic back-
grounds, especially in the Asian population, are required to
determine the genetic diversity of rare genetic variations in the
human population.
We observed that most of the functionally important amino acid
residues in the six LOX genes are not affected by genetic variations.
Thus, one might conclude that there is an evolutionary pressure on
these residues to keep the functionality of these enzymes. Similar
predictions were made for other enzymes evaluating the data from
the human 1000 Genome project [28,59]. Although the exact
biological role of the six LOX isoforms is not clear at the moment,
these enzymes are well-conserved in two of the three major
domains of terrestrial life, which indicates a biological role in living
organisms [4]. Mammalian ALOX5 catalyzes the rate-limiting step in
the biosynthesis of pro-inﬂammatory leukotrienes (LTs), which have
been implicated in the pathogenesis of different inﬂammatory
diseases [1]. Epidermal LOX isoforms (ALOX12B, ALOXE3) appear
to be essential for the epidermal barrier formation and for skin
development [25,57]. hALOX15 has been implicated in the synthesis
of atheroprotective lipoxins and resolvins [65] and heterozygous
carriers of the Thr560Met allele (rs34210653; global allele frequency
1.5%) have an increased risk in developing CAD [22]. We recently
reported that the hALOX15 SNP rs61099320, which represents a
Gly422Glu exchange, leads to a near-null variation of this enzyme
which is related to protein misfolding [24].
Most of the detected genetic variations in LOXs encode for
surface exposed amino acids. Since the active site of the enzyme
is buried deeply inside the protein, surface exposed mutations are
less likely to have functional consequences. However, since LOXs
might function as dimers, surface exposed variations might well be
of functional importance. [66]. A non-synonymous coding SNP in
the human dopamine β-Hydroxylase gene showed that it prevents
the tetramerization of the enzyme which is essential for its
functionality [67]. Alternatively, SNPs at the protein surface might
be important for the intracellular interaction with other regulatory
proteins [68], but both aspects were not addressed by our experi-
mental approach. Moreover, non-synonymous coding SNPs may be
of a biological relevance since the binding of regulatory proteins
during transcription, translation and mRNA processing (splicing)
might be affected by such genetic variations [69–70]. To study the
functional consequences of such non-synonymous coding variations
on the DNA- or RNA level a completely different methodology must
be applied.
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